Oryon Cell Therapies, a clinical-stage biotech company, has emerged from stealth mode to focus on developing an autologous neuron replacement therapy for Parkinson’s disease and other neurodegenerative disorders. The company has secured $42 million in funding, including a new $21 million Series A tranche, to support the completion of its Phase 1b/2a clinical trial.
Ron Cohen, MD, has been appointed as CEO, bringing his 30-year experience in developing and commercializing novel medicines for neurological conditions. Early clinical data from Oryon’s lead program show motor improvements and neuroimaging evidence of restored dopaminergic signaling, which is a significant milestone in the treatment of Parkinson’s disease.
Oryon’s therapy uses autologous blood cells to create pluripotent stem cells, which are then induced to become dopamine-producing neurons. This approach eliminates the need for immune suppression, making it a promising treatment option for patients with Parkinson’s disease.
The company plans to use its funding to advance its lead program to a Phase 3 trial and expand its research into other neurodegenerative disorders. With its innovative technology and experienced leadership team, Oryon Cell Therapies is poised to make a significant impact in the fight against Parkinson’s disease and other neurological conditions.
Source: https://www.morningstar.com/news/business-wire/20260323924704/oryon-cell-therapies-emerges-from-stealth-focusing-on-autologous-neuron-replacement-therapies-for-parkinsons-disease-and-other-neurodegenerative-disorders